JPRN-UMIN000007803招募中2 期
The efficacy and safety of subcutaneous injection of bortezomib combined with doxorubicin and dexamethasone for untreated multiple myeloma patients. - The efficacy and safety of sPAD
ational Hospital Organization Disaster Medical Center0 个研究点目标入组 35 人开始时间: 2012年4月21日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •The exclusion criteria were a serum creatinine level>2.05 mg/dL, liver dysfunction (e.g., a serum total bilirubin level>2.0 mg/dL, or serum aspartate/alanine aminotransferase or alkaline phosphatase levels more than 2.5 times the upper limit of normal), grade 3 or worse peripheral neuropathy, significant comorbidity that would preclude ASCT, poor performance status (>grade 3), and a history of any other malignancy with the exception of basal cell carcinoma and stage I cervical cancer.
研究者
相似试验
进行中（未招募）
不适用
Efficacy and Safety of subcutaneous administration of XM01 and Epoetin beta for treatment of anaemia in chronic renal failure patients not yet receiving dialysis. A multinational, multicentre, randomised, controlled, double-blind, parallel group phase II study.EUCTR2005-000140-85-HUBioGeneriX AG150
进行中（未招募）
不适用
Efficacy and Safety of subcutaneous administration of XM01 compared to Epoetin beta in anaemic chronic renal failure patients not yet receiving dialysis and in maintenance phase treatment with Epoetin beta. A multinational, multicentre, randomised, controlled, double-blind, comparative, parallel group Phase III study.anaemic chronic renal failure patients not yet receiving dialysisMedDRA version: 9Level: LLTClassification code 10009119EUCTR2005-000142-37-HUBioGeneriX AG255
已完成
4 期
Efficacy and Safety of Subcutaneous Administration of Lyophilized Powder of Alpha-Erythropoietin to Maintains Hemoglobin Concentrations among Hemodialysis PatientsAnemia associated with chronic kidney diseaseHemodialysisLyophilised powderErythropoietinAnemiaTCTR20161214001Phramongkutklao hospital and College of Medicine63
进行中（未招募）
1 期
Safety and efficacy of subcutaneous (SC) administration of Clinimix N9G15E in elderly patients at risk for malnutrition, at a dose of 1 liter infused over 12 hours for 7 to 10 consecutive days. A prospective, multicentre, randomized, open-label, non-inferiority, controlled phase III B trial carried out in parallel groups: subcutaneous versus peripheral intravenous administration.EUCTR2007-006153-31-FRBaxter R and D Europe SCR120
已完成
3 期
The saftey and efficacy of intradermal injection of type A butulinum toxin in chemotherapy induced peripheral neuropathyChemotherapy induced neuropathy.IRCT20200425047202N1Shahid Beheshti University of Medical Sciences40